Advancing Abbott Acquisition of Piramal's Healthcare Solutions Business

Advancing Abbott Acquisition of Piramal's Healthcare Solutions Business

Abbott Strategy

Further diversify sources of pharmaceutical growth

• Abbott will become No. 1 in India, with ~20% annual growth over next several years

• Piramal to add >$500MM in 2011 sales in India; total Abbott pharma sales expected to exceed $2.5BN by 2020 in India

• Builds on Solvay acquisition and Zydus collaboration

Expand presence in high-growth emerging markets

• India is one of the world's fastest-growing markets; expected to more than double by 2015

• Piramal has the largest sales force in India; unique model with dedicated people in high-growth rural areas

Establish a leading presence in branded generics

• Piramal portfolio has ~350 leading branded generics in multiple therapeutic areas

• Solvay, Zydus and Piramal give Abbott critical mass and a comprehensive leading portfolio of branded generics

Deliver sustained double-digit EPS growth

• Expect ~20% Piramal sales growth over the next five years

• Expect transaction to be neutral to EPS over the next several years, accretive thereafter

Source: Abbott